BPC-157 and TB-500 peptide claims: what the science actually supports

What did @hacksmith_peptalk actually say?

The creator claims that delta sleep-inducing peptide, or DSIP, is "the greatest peptide for sleep" they have ever experienced. They report personal Garmin watch sleep scores jumping from a baseline of around 65 to the low 80s after taking DSIP. They describe taking it intranasally at 150 to 200 micrograms, two to three hours before bed. They also say it improves deep sleep in the first half of the night and REM sleep in the second half, and that it helps regulate cortisol and promotes relaxation.

To be clear: this is an n=1 anecdote backed by a consumer wearable device. That does not make it false, but it does set a low evidentiary bar, and that context matters before we dig into the science.

Does the science back this up?

Partially, but the evidence base is thin and mostly old. DSIP was first isolated in 1974 by Monnier et al. from rabbit cerebral venous blood, and early animal studies showed genuine sleep-promoting effects. Human data is limited and inconsistent.

A 1984 study by Schoenenberger et al. in the European Journal of Pharmacology found that intravenous DSIP administration did modestly increase slow-wave sleep in some human subjects, which aligns loosely with what the creator describes as deeper sleep in the first portion of the night. However, the effect sizes were modest and results varied widely between individuals.

On cortisol regulation, there is some supporting data. Kastin et al. (1981, Pharmacology Biochemistry and Behavior) noted DSIP appeared to influence stress hormone levels in animal models, but translating that to human intranasal dosing is a leap. Intranasal bioavailability of peptides varies enormously depending on molecular weight and formulation, and DSIP has not been studied this way in controlled human trials.

Consumer sleep trackers like Garmin are also not validated tools for staging sleep architecture. A score jumping from 65 to 82 is not the same as a polysomnography showing more Stage N3 or REM sleep.

What did they get wrong (or right)?

They got the general mechanism in the right neighborhood. DSIP does appear to interact with neurotransmitter systems involved in sleep, including opioid and serotonergic pathways, though calling it simply "interact with some of the neurotransmitters" is vague enough to be technically not wrong.

Where the video goes sideways is the confidence level. Saying this is the "greatest peptide for sleep" based on personal Garmin scores is not a scientific conclusion. Garmin's sleep scoring algorithm is proprietary and not validated against polysomnography for detecting changes in sleep stages caused by peptides.

The claim that REM sleep is "significantly improved" is also overreaching. The early DSIP literature focused primarily on slow-wave sleep, not REM. If REM improvements are occurring here, they are either a secondary or placebo effect, or simply noise in a consumer device algorithm.

Credit where it is due: the dosing range mentioned (150 to 200 micrograms) is consistent with what appears in informal research communities, and the intranasal route is plausible given DSIP's small molecular size, roughly 850 daltons, which is within the range of peptides that can cross nasal mucosa.

What should you actually know?

DSIP is not FDA-approved for any indication. It is not a compounded drug with established clinical protocols. Research on it essentially stalled in the 1980s and 1990s, and there are no large-scale human randomized controlled trials evaluating safety or efficacy for sleep improvement.

The peptide exists in a legal gray zone in the United States. It is not a scheduled substance, but it is also not approved for human use. Purchasing it typically means buying from research chemical suppliers with variable quality control.

If you are struggling with sleep, there are interventions with far stronger evidence behind them. Cognitive behavioral therapy for insomnia, or CBT-I, has multiple meta-analyses supporting it as first-line treatment. Sleep hygiene interventions and addressing underlying conditions like sleep apnea have actual clinical trial data. DSIP does not.

Anyone considering peptide therapy for sleep should do so under the supervision of a licensed provider who can order validated testing, not just read Garmin watch data, and who understands the regulatory and safety context of these compounds.